| Literature DB >> 33046687 |
Wen-He Yang1, Liang Zhang1, Fu-Shan Xue1, Azmat Riaz2, Zhi-Jun Zhu3,4,5.
Abstract
BACKGROUND Alagille syndrome (AGS) is an autosomal dominant hereditary disorder characterized by identifiable abnormalities in the liver, heart, face, skeleton, and eyes. Recently, liver transplantation (LT) has been proposed as a therapeutic strategy for patients with AGS complicated by end-stage liver disease, but clinical experience in performing anesthesia in LT for AGS is still scarce. We aimed to summarize our preliminary experience in the anesthetic management of LT for AGS in this study. MATERIAL AND METHODS We reviewed the cases of 11 patients with AGS who underwent LT from September 2017 to April 2019. Preoperative multi-system comorbidities, intraoperative details, and postoperative outcomes were retrospectively collected and summarized. RESULTS Cardiopulmonary abnormalities were common (81.8%) in AGS patients before LT, and the most frequent comorbidity was pulmonary artery stenosis. After careful anesthetic evaluation and perioperative management, all patients survived during the perioperative period without significant cardiovascular complications. However, there was an unexpectedly high prevalence of surgical complications and re-operations in AGS patients compared to biliary atresia recipients (54.5% vs. 22.4%, P=0.031; and 45.5% vs. 15.3%, P=0.028, respectively). CONCLUSIONS Perioperative management of LT for AGS patients can be particularly challenging, requiring a full understanding of the pathophysiology, as well as a careful preoperative evaluation of the multi-system comorbidities. The high prevalence of postoperative surgical complications should be a matter of concern.Entities:
Year: 2020 PMID: 33046687 PMCID: PMC7568439 DOI: 10.12659/AOT.924282
Source DB: PubMed Journal: Ann Transplant ISSN: 1425-9524 Impact factor: 1.530
Baseline patient and liver graft characteristics.
| Case | Age (mo) | Gender | Weight (kg) | Height (cm) | Z Score | Genetic type | CTP Score | PELD Score | Echocardiogram Abnormities | NYHA Classification |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 12 | Female | 7.5 | 66 | −3.60 | JAG1 | 8 | 12 | PFO, PAS | I |
| 2 | 27.5 | Male | 10.5 | 82 | −2.68 | 6 | 8 | Normal | I | |
| 3 | 12 | Male | 9 | 82 | 1.96 | JAG1 | 8 | 13 | VSD, PDA | I |
| 4 | 149 | Male | 35.8 | 143 | −1.03 | JAG1 | 6 | 13 | PS | I |
| 5 | 16.5 | Male | 8.4 | 76 | −1.31 | JAG1 | 9 | 18 | Normal | I |
| 6 | 73 | Male | 15 | 102 | −3.49 | JAG1 | 5 | −3 | VSD | II |
| 7 | 65.5 | Male | 15 | 97 | −4.12 | JAG1 | 12 | 31 | PS | II |
| 8 | 23.5 | Female | 8.5 | 80 | −2.25 | 9 | 21 | BAVS | II | |
| 9 | 17 | Male | 7.9 | 71.5 | −2.96 | JAG1 | 8 | 12 | PFO | I |
| 10 | 12 | Female | 6.3 | 68 | −2.80 | JAG1 | 7 | 10 | PS | I |
| 11 | 114 | Male | 17 | 122 | −2.69 | JAG1 | 5 | 3 | PS | I |
| 1 | Deceased | Whole | 321 | 4.28 | 5 | 710 | ||||
| 2 | Living related | Left lateral lobe | 226 | 2.15 | 2 | 83 | ||||
| 3 | Living related | Left lateral lobe | 267 | 2.97 | 2 | 117 | ||||
| 4 | Deceased, split | Left lobe with MHV | 525 | 1.47 | 3 | 570 | ||||
| 5 | Deceased, reduced-size | Left lateral lobe | 264 | 3.14 | 3 | 640 | ||||
| 6 | Living related | Left lateral lobe | 317 | 2.11 | 4 | 147 | ||||
| 7 | Living related | Left lobe with MHV | 306 | 2.04 | 2 | 150 | ||||
| 8 | Living related | Left lateral lobe | 214 | 2.52 | 2 | 90 | ||||
| 9 | Living related | Left lateral lobe | 253 | 3.20 | 2 | 79 | ||||
| 10 | Living related | Left lateral lobe | 200 | 3.18 | 1 | 67 | ||||
| 11 | Living related | Left lateral lobe | 272 | 1.60 | 2 | 100 | ||||
Diagnosis based on clinical diagnostic criteria.
Height for age Z score (Data form Chinese Center for Disease Control and Prevention).
BAVS – bicuspid aortic valve stenosis; CIT – cold ischemia time; CTP – Child-Turcotte-Pugh; GRWR – graft-to-recipient weight ratio; MHV – middle hepatic vein; PAS – pulmonary artery sling; PDA – patent ductas arteriosus; PELD – Pediatric End-stage Liver Disease; PFO – patent foramen ovale; PS – pulmonary stenosis; VSD – ventricular septal defect; WIT - warm ischemia time.
Intraoperative hemodynamics, electrolyte, and blood gas measurements.
| Variables | Anesthetic induction | Anhepatic phase | Post-reperfusion | End of operation |
|---|---|---|---|---|
| HR (bpm) | 109.0±6.3 | 127.8±7.8 | 116.0±7.3 | 107.4±5.9 |
| SAP (mm Hg) | 90.2±2.8 | 95.1±3.9 | 64.3±2.6 | 93.9±1.6 |
| CVP (mm Hg) | 5.7±0.7 | 5.2±0.8 | 4.6±0.9 | 7.2±0.8 |
| pH | 7.35±0.1 | 7.35±0.2 | 7.29±0.2 | 7.36±0.2 |
| PaCO2 (mm Hg) | 39.5±1.8 | 36.5±1.4 | 41.4±1.2 | 41.8±1.7 |
| PaO2 (mm Hg) | 299.9±10.3 | 314.8±8.9 | 293.0±8.7 | 360.9±9.5 |
| BE (mmol/L) | −3.6±1.1 | −4.9±1.2 | −5.9±1.2 | −2.1±0.7 |
| HCO3 (mmol/L) | 21.7±1.1 | 20.5±1.0 | 20.1±0.9 | 23.1±0.6 |
| Na (mmol/L) | 133.3±1.1 | 137.6±1.2 | 139.3±1.1 | 144.3±1.0 |
| K (mmol/L) | 3.9±0.2 | 4.0±0.2 | 3.7±0.2 | 4.2±0.1 |
| Ca (mmol/L) | 1.18±0.02 | 1.11±0.04 | 1.14±0.06 | 1.08±0.03 |
| GLU (mmol/L) | 6.0±0.8 | 7.5±1.2 | 9.5±1.5 | 8.9±1.0 |
| LAC (mmol/L) | 0.8±0.1 | 2.2±0.2 | 3.8±0.4 | 2.6±0.3 |
| HCT (%) | 28.4±1.3 | 28.3±1.5 | 27.0±2.2 | 28.5±1.3 |
Compared with variables after anesthetic induction (P<0.05).
Compared with variables before reperfusion (P<0.05).
BE – base excess; Ca – serum calcium concentration; CVP – central venous pressure; GLU – blood glucose concentration; HCT – hematocrit; HR – heart rate; K – serum potassium concentration; LAC – blood lactate concentration; SAP – systolic arterial pressure; Na – serum sodium concentration; PaCO2 – arterial carbon dioxide pressure; PaO2 – arterial oxygen pressure.
Intraoperative management and postoperative outcomes.
| Case | Fluid infusion (ml/kg/h) | Blood loss (ml/kg) | Urine output (ml/kg/h) | RBC (ml/kg) | FFP (ml/kg) | ICU stay (days) | Hospital stay (days) | Surgical complications | Re-operation | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 7.6 | 10.67 | 4.8 | 26.67 | 13.33 | 7.5 | 30 | HAT | None | Alive |
| 2 | 12.1 | 7.62 | 6.3 | 0 | 0 | 20 | 56 | BL, HVAS | Choledochojeju-nostomy | Alive |
| 3 | 13.6 | 38.89 | 6.8 | 33.33 | 0 | 3 | 30 | WI,WD | Exploratory laparotomy | Alive |
| 4 | 7.8 | 36.31 | 3.2 | 36.31 | 16.76 | 2.5 | 38 | None | None | Alive |
| 5 | 13.9 | 16.67 | 3.7 | 23.81 | 0 | 3.5 | 23 | None | None | Alive |
| 6 | 6.3 | 8.00 | 4.1 | 0 | 0 | 4.5 | 16 | None | None | Alive |
| 7 | 9.4 | 33.33 | 3.5 | 40.00 | 0 | 9 | 37 | IP | Exploratory laparotomy, IPR | Alive |
| 8 | 10.8 | 5.90 | 3.4 | 0 | 0 | 5 | 43 | None | None | Alive |
| 9 | 16.2 | 25.32 | 4.6 | 25.32 | 0 | 15 | 44 | IP | IPR | Alive |
| 10 | 19.7 | 31.75 | 7.9 | 31.75 | 0 | 2.5 | 51 | None | None | Alive |
| 11 | 9.2 | 14.71 | 3.7 | 11.76 | 0 | 7.5 | 21 | Roux-en-Y anastomotic bleeding | Exploratory laparotomy | Alive |
BL – bile leakage; FFP – fresh frozen plasma; HAT – hepatic artery thrombosis; HVAS – hepatic vein anastomotic stricture; ICU – Intensive Care Unit; IP – intestinal perforation; IPR – intestinal perforation repair; RBC – red blood cell; WD – wound dehiscence; WI – wound infection.
Postoperative surgical complications and re-operations in pediatric AGS and BA recipients.
| Variables | AGS (n=11) | BA (n=98) | P-value |
|---|---|---|---|
| Age (mo) | 23.5 (12.0–73.0) | 30.9 (10.3–73.3) | 0.007 |
| Male gender (%) | 8 (72.7) | 54 (55.1) | 0.345 |
| Height (cm) | 82.0 (71.5–102.0) | 70.0 (65.4–90.3) | 0.038 |
| Weight (kg) | 8.5 (7.5–15) | 8.5 (7.0–13.3) | 0.466 |
| Z Score | −2.69 (−3.49 – −1.31) | −1.18 (−2.30 – −0.13) | 0.015 |
| PELD score | 9 (3–15) | 10 (−3–21) | 0.759 |
| Preoperative history of abdominal operation (%) | 9 (81.8) | 90 (91.8%) | 0.265 |
| Living-related donor (%) | 8 (72.7) | 75 (76.5) | 0.722 |
| Partial graft (%) | 10 (90.9) | 78 (79.6) | 0.687 |
| Graft weight (g) | 267 (226–317) | 259 (210–326) | 0.644 |
| GRWR (%) | 2.68±0.91 | 2.92±0.96 | 0.432 |
| Surgical complications | 6 (54.5) | 22 (22.4) | 0.031 |
| Re-operations (%) | 5 (45.5) | 15 (15.3) | 0.028 |
Height for age Z score (Data form Chinese Center for Disease Control and Prevention).
AGS – Alagille syndrome; BA – biliary atresia; GRWR – graft-to-recipient weight ratio; LT – liver transplantation; PELD – Pediatric End-stage Liver Disease.